UBS AM’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-70,721
| Closed | -$3.65M | – | 2806 |
|
|
2022
Q3 | $3.65M | Buy |
70,721
+768
| +1% | +$31.7K | ﹤0.01% | 1314 |
|
|
2022
Q2 | $1.73M | Buy |
69,953
+971
| +1% | +$21.4K | ﹤0.01% | 1679 |
|
|
2022
Q1 | $1.73M | Sell |
68,982
-9,576
| -12% | -$269K | ﹤0.01% | 1868 |
|
|
2021
Q4 | $2.86M | Buy |
78,558
+8,726
| +12% | +$306K | ﹤0.01% | 1699 |
|
|
2021
Q3 | $1.19M | Sell |
69,832
-23,233
| -25% | -$362K | ﹤0.01% | 2071 |
|
|
2021
Q2 | $1.25M | Buy |
93,065
+33,725
| +57% | +$831K | ﹤0.01% | 2090 |
|
|
2021
Q1 | $3.04M | Buy |
59,340
+1,094
| +2% | +$65.8K | ﹤0.01% | 1577 |
|
|
2020
Q4 | $3.61M | Buy |
58,246
+10,224
| +21% | +$585K | ﹤0.01% | 1432 |
|
|
2020
Q3 | $2.63M | Sell |
48,022
-273
| -0.6% | -$14.7K | ﹤0.01% | 1434 |
|
|
2020
Q2 | $2.78M | Buy |
48,295
+9,159
| +23% | +$498K | ﹤0.01% | 1391 |
|
|
2020
Q1 | $1.57M | Sell |
39,136
-7,937
| -17% | -$337K | ﹤0.01% | 1515 |
|
|
2019
Q4 | $1.86M | Buy |
47,073
+11,285
| +32% | +$198K | ﹤0.01% | 1632 |
|
|
2019
Q3 | $243K | Buy |
35,788
+14,145
| +65% | +$106K | ﹤0.01% | 2517 |
|
|
2019
Q2 | $201K | Buy |
+21,643
| New | +$251K | ﹤0.01% | 2544 |
|
|
2018
Q4 | – | Sell |
-16,700
| Closed | -$211K | – | 2838 |
|
|
2018
Q3 | $211K | Hold |
16,700
| – | – | ﹤0.01% | 2421 |
|
|
2018
Q2 | $220K | Buy |
+16,700
| New | +$200K | ﹤0.01% | 2439 |
|
Other funds holding CCXI
UBS AM's CCXI Position: Q4 2022 in Review
UBS AM sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 70,721 shares — an estimated $3.65M sold.
UBS AM first reported a position in CCXI in Q2 2018 and held it in 16 quarters. The position peaked at $3.65M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- UBS AM reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- UBS AM sold 70,721 ChemoCentryx, Inc. shares in Q4 2022, an estimated $3.65M.
- UBS AM first reported a position in ChemoCentryx, Inc. in Q2 2018 and held it in 16 quarters.
- UBS AM's ChemoCentryx, Inc. position peaked at $3.65M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.